Detailed answers about READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD, including incorporation, status, business activity, and accounts information.
When was READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD founded?
READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD was officially incorporated on 10 October 2025 and is registered under company number 16776818. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD?
READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD do?
READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD operates in the following sector: 86220 - Specialists medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD's registered address?
The registered office address of READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD is 17 PANTERS ROAD, CHOLSEY, WALLINGFORD, ENGLAND, OX10 9NY. This is the official address filed with Companies House for legal and statutory correspondence.
Is READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD financially stable?
Financial accounts for READING ENDOCRINOLOGY, DIABETES AND LIPIDS LTD are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.